

Atsunari Kawashima

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2092907/publications.pdf>

Version: 2024-02-01

19
papers

392
citations

840776

11
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

689
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic potential of <i>TERT</i> promoter and <i>FGFR3</i> mutations in urinary cell-free DNA in upper tract urothelial carcinoma. <i>Cancer Science</i> , 2019, 110, 1771-1779.	3.9	63
2	Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. <i>Cancer Science</i> , 2019, 110, 617-628.	3.9	61
3	Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5390.	4.1	48
4	Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers. <i>Cancer Science</i> , 2021, 112, 2033-2045.	3.9	35
5	The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 588-594.	2.1	28
6	Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6220.	3.3	25
7	PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN- γ production, but lose cytotoxic activity in ovarian cancer. <i>International Immunology</i> , 2020, 32, 397-405.	4.0	22
8	Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN). <i>Journal of the National Cancer Institute</i> , 2020, 112, 1098-1104.	6.3	21
9	Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 113-125.	4.2	20
10	MicroRNA-2b is a prognostic oncomiR that targets <i>TSC1</i> in clear cell renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1146-1155.	3.9	19
11	Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer. <i>Cancer Science</i> , 2020, 111, 1692-1698.	3.9	12
12	Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma. <i>Cancer Science</i> , 2022, 113, 1830-1842.	3.9	11
13	Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. <i>International Immunology</i> , 2020, 32, 347-357.	4.0	10
14	Fragmentation of cell-free DNA is induced by upper-tract urothelial carcinoma-associated systemic inflammation. <i>Cancer Science</i> , 2021, 112, 168-177.	3.9	6
15	Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2022, 29, 462-469.	1.0	6
16	Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2999-3011.	4.2	4
17	A case of perirenal non-specific lymphadenitis mimicking a solitary renal mass. <i>IJU Case Reports</i> , 2022, 5, 10-13.	0.3	1
18	Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space. <i>IJU Case Reports</i> , 2021, 4, 255-258.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Biological distinction between grades 2 and 3 with respect to intravesical recurrence in T1 high-grade bladder tumors: a retrospective study. BMC Urology, 2022, 22, 59.	1.4	0